118 related articles for article (PubMed ID: 36038467)
1. Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer.
Akagündüz B; Guven DC; Ozer M; Okten IN; Atag E; Unek İT; Tatli AM; Karaoglu A
J Geriatr Oncol; 2023 Mar; 14(2):101367. PubMed ID: 36038467
[No Abstract] [Full Text] [Related]
2. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
3. New Insights into Adjuvant Therapy for Localized Colon Cancer.
González NS; Ros Montaña FJ; Illescas DG; Argota IB; Ballabrera FS; Élez Fernández ME
Hematol Oncol Clin North Am; 2022 Jun; 36(3):507-520. PubMed ID: 35577707
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives.
Merk C; Martling A; Lindberg J; Benhaim L; Taieb J; Lind P
Acta Oncol; 2022 Apr; 61(4):523-530. PubMed ID: 35139729
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
[TBL] [Abstract][Full Text] [Related]
6. "Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".
Taïeb J; Benhaim L; Laurent Puig P; Le Malicot K; Emile JF; Geillon F; Tougeron D; Manfredi S; Chauvenet M; Taly V; Lepage C; André T
Dig Liver Dis; 2020 Jul; 52(7):730-733. PubMed ID: 32482534
[TBL] [Abstract][Full Text] [Related]
7. Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?
Morris VK; George TJ
Clin Cancer Res; 2022 Feb; 28(3):438-440. PubMed ID: 34848532
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
Tie J; Wang Y; Tomasetti C; Li L; Springer S; Kinde I; Silliman N; Tacey M; Wong HL; Christie M; Kosmider S; Skinner I; Wong R; Steel M; Tran B; Desai J; Jones I; Haydon A; Hayes T; Price TJ; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Sci Transl Med; 2016 Jul; 8(346):346ra92. PubMed ID: 27384348
[TBL] [Abstract][Full Text] [Related]
9. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study.
Li Y; Mo S; Zhang L; Ma X; Hu X; Huang D; Lu B; Luo C; Peng H; Cai S; Sheng W; Peng J
Eur J Cancer; 2022 Jul; 169():198-209. PubMed ID: 35636041
[TBL] [Abstract][Full Text] [Related]
10. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217).
Folprecht G; Reinacher-Schick A; Weitz J; Lugnier C; Kraeft AL; Wisser S; Aust DE; Weiss L; von Bubnoff N; Kramer M; Thiede C; Tannapfel A
Clin Colorectal Cancer; 2022 Jun; 21(2):170-174. PubMed ID: 34772609
[TBL] [Abstract][Full Text] [Related]
11. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
12. ctDNA-guided adjuvant chemotherapy for colorectal cancer-ready for prime time?
Andersen CL; Heitzer E
Cancer Cell; 2022 Sep; 40(9):911-913. PubMed ID: 36055230
[TBL] [Abstract][Full Text] [Related]
13. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA).
Verbus EA; Rossi AJ; Luna AJ; Iqbal A; Morris VK; Hernandez JM
Ann Surg Oncol; 2021 Aug; 28(8):4095-4097. PubMed ID: 33999346
[No Abstract] [Full Text] [Related]
15. Adjuvant chemotherapy guided by circulating tumour DNA in stage II colon cancer.
Hindson J
Nat Rev Gastroenterol Hepatol; 2022 Aug; 19(8):488. PubMed ID: 35773389
[No Abstract] [Full Text] [Related]
16. Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials.
Conca V; Ciracì P; Boccaccio C; Minelli A; Antoniotti C; Cremolini C
Cancer Treat Rev; 2024 May; 126():102735. PubMed ID: 38613871
[TBL] [Abstract][Full Text] [Related]
17. ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis.
Yekedüz E; Köksoy EB; Akbulut H; Ürün Y; Utkan G
Future Oncol; 2021 Jan; 17(3):349-357. PubMed ID: 33356539
[No Abstract] [Full Text] [Related]
18. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.
Qiu B; Guo W; Zhang F; Lv F; Ji Y; Peng Y; Chen X; Bao H; Xu Y; Shao Y; Tan F; Xue Q; Gao S; He J
Nat Commun; 2021 Nov; 12(1):6770. PubMed ID: 34799585
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a
Taieb J; Taly V; Henriques J; Bourreau C; Mineur L; Bennouna J; Desrame J; Louvet C; Lepere C; Mabro M; Egreteau J; Bouche O; Mulot C; Hormigos K; Chaba K; Mazard T; de Gramont A; Vernerey D; André T; Laurent-Puig P
Clin Cancer Res; 2021 Oct; 27(20):5638-5646. PubMed ID: 34083233
[TBL] [Abstract][Full Text] [Related]
20. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
